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Abstract. Acute i.p. administration of morphine or 
cocaine produced increase in locomotor activity in 
Swiss-Webster female mice that were maximal at 3 2 -  
100 mg/kg for morphine and at 32 mg/kg for cocaine. 
WIN35,197-2 produced dose-dependent decreases in 
locomotor activity from 3 .2 -  32 mg/kg. Chronic ad- 
ministration of WIN35,197-2 led to a 6 -  10 fold shift 
to the right in the locomotor activity decreasing effect 
of the drug, but WIN35,197-2-tolerant mice retained 
their sensitivity to the locomotor stimulant effects of 
morphine and cocaine. Acute administration of 
WIN35,197-2 failed to sensitize mice to naloxone- 
induced jumping, although morphine did so. Chronic 
administration of WIN35,197-2 did lead to sensiti- 
zation to naloxone, but WIN 35,197-2 was much less 
efficacious in this regard than morphine. These behav- 
ioral effects of WIN35,197-2 may be helpful in the 
classification of modes of action of different narcotic 
agonists. 
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Evidence has been obtained recently for multiple modes 
of action of different narcotic agonists. Comparisons 
have been drawn particularly to differences between the 
ketazocines (e.g., ketazocine and WIN 35, 197-2, also 
referred to as ethylketazocine; see Figure I for struc- 
tural formulas) and morphine-like drugs. The keta- 
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zocines appear to share many of the actions of cycla- 
zocine, while being virtually devoid of cyclazocine's 
narcotic antagonist activity (e.g., Kosterlitz and 
Waterfield, 1975; W. Michne, personal communi- 
cation). Using in vitro preparations, Lord et al. (1977) 
demonstrated that a variety of 6,7-benzomorphans, 
including WIN35,197-2, are relatively less potent 
than morphine-like compounds in depressing electri- 
cally induced contractions of the vas deferens of the 
mouse as compared to electrically induced contrac- 
tions of the ileum of guinea pigs. In addition, the 
ketazocine-like compounds require larger amounts of 
naloxone relative to morphine to reverse comparable 
actions in these preparations (Hutchinson et al., 1975). 
Gilbert and Martin (1976), using the chronic spinal 
dog, showed that WIN35,197-2 had relatively less 
efficacy than morphine in changing respiratory rate, 
decreasing body temperature, and altering the skin 
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Fig. 1. Structural formulas of cyclazocine, some of its congeners, and 
morphine 
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twitch reflex. Morph ine  and  W I N  35,197-2 had com- 
parable effects in reducing the flexor reflex, while 
WIN35,197-2  was a stronger mydriatic.  Thus  mor-  
phine and W I N  35,197-2 have different spectra of  acute 
behavioral  and physiological actions in the dog. 
Fol lowing chronic morph ine  adminis t ra t ion,  neither 
ketazocine nor  W I N  35,197-2 suppresses specific signs 
of the morphine  abst inence syndrome in the dog 
(Mar t in  et al., 1976) or the rhesus monkey  (H. Swain, 
personal  communica t ion) .  
The purpose of the present set of  experiments was to 
compare  the effects of W I N  35,197-2 and  morph ine  on 
locomotor  activity in the mouse;  morph ine  produces a 
characteristic increase in mouse locomotor  activity 
(e.g., Goldste in  and  Sheehan, 1969; Rethy et al., 1971). 
In  addit ion,  we studied WIN35,197-2  to determine 
whether tolerance would occur to its effects on  loco- 
motor  activity and,  if so, whether cross tolerance to 
morphine  would be found.  We also examined whether 
na loxone  would induce j ump ing  behavior  following 
acute and  chronic W I N  35,197-2 adminis t ra t ion ;  na-  
loxone readily induces this j u m p i n g  following acute 
morph ine  adminis t ra t ion  (e.g. Jacob et al., 1974), and 
the behavior  occurs at a greater rate with na loxone  
following chronic morph ine  adminis t ra t ion  (e.g. 
Hu idobro  et al., 1963). 
same volume of vehicle. Following the injection, the mouse was 
immediately placed in the locomotor activity cage and, when the six 
injections were completed, activity was measured for 1 h. After the 
mice were taken out of the locomotor activity apparatus, they were 
injected with 16 mg/kg naloxone and placed in the jars for a 10-rain 
observation period of jumping behavior. 
Chronic administration studies were carried out over 4-day 
periods. Mice were injected once every 8 h for 3 days with either 
morphine or WIN 35,197-2. Injections were given at 08:00, 16:00, 
and 24:00 with initial injections starting at 08:00. On the 4th day, 
instead of the routine injection at 8 a.m., the mice received other doses 
of the same drug or a different drug and observations were made on 
locomotor activity and naloxone-induced jumping under the same 
conditions as with acute administration. The group of mice receiving 
morphine was given 100 mg/kg every 8 h and on the 4th day received a 
variety of morphine doses. Additional mice treated daily with 
morphine received 100mg/kg cocaine on the 4th day. The mice 
receiving l0 mg'kg of WIN 35,197-2 on the first day were injected 
with 32mg/kg of this drug on the second and 3rd days. On the 
4th day, half of the group received different doses of WIN 35,197-2; 
the other half received various doses of morphine. Additional mice 
from this group were given 100 mg/kg cocaine. 
Mean locomotor activity, mean jumping activity, and their 
standard errors were determined. Significance of differences between 
means was evaluated by t-tests (two-tailed) and P values are reported. 
Drugs. The morphine sulfate, naloxone hydrochloride, and cocaine 
hydrochloride used in this study were dissolved in 0.9 % saline. 
WIN 35,197-2, also known as ethylketocylazocine, was dissolved in 
distilled Water with a small amount of lactic acid; sodium bicarbonate 
was used to bring the pH of the solution up to about4. The 
benzomorphan was generously supplied by Sterling-Winthrop and 
the naloxone by Endo Labs. 
Materials and Methods 
Subjects. The mice used in this study were obtained from Spartan 
Research Animals, Haslett, Michigan, and were albino females of the 
Swiss-Webster strain, weighing 25 -35 g. The mice were housed in a 
30 x 60 • 15 cm group cages in a rodent colony room for 3 - 7  days 
prior to use. They were fed Purina Chow, and water was also 
freely available; the lights were on from 8 a.m. to 8 p.m. Each mouse 
was used only once. 
Apparatus. The six locomotor activity cages were located in a light- 
and sound-attenuated chamber. Masking noise and ventilation were 
provided by an exhaust fan. Each mouse was placed in a separate 
circular cage 30.5 cm in diameter and 8 cm in height. The cages were 
equipped with two light sources and photocells arranged so that the 
light beams intersected perpendicularly. Interruption of a beam 
triggered a pulse former and subsequently registered on a counter; the 
number of counts in an hour was taken as the measure of locomotor 
activity. 
For observation of jumping behavior, each mouse was placed 
in a one-gallon glass jar (15 cm diameter, 25 cm high) with the lid 
turned over and slightly off center. Four to six mice were observed at 
a time, and jumps were counted by hand on push- button switches 
attached to pulse counters. A jump was registered when all paws left 
the floor of the jar. Other activities (e.g., rearing and attempts to 
'climb the sides') were excluded. The jumps were counted in a 10-min 
period immediately following i,p. injection of naloxone. 
Procedure. Dose-response curves for locomotor activity in naive mice 
were obtained for morphine, WIN 35,197-2, and cocaine. For each 
1 h period of locomotor activity measurement, five mice were injected 
with 0.1 ml/10 g body weight of a drug and one was injected with the 
Results 
Locomotor Activity. WI N  35,197-2 had only a slight 
effect at 1 mg/kg, but  it significantly ( P <  0.01) de- 
pressed locomotor  activity at 3.2, 10, and  32mg/kg  
(Fig. 2). At  the highest dose, the animals  were virtually 
immobile.  At  these high doses hypervent i la t ion and  
splayed hind limbs were p rominen t  signs; when 
touched, the mice swayed, moved slightly, and  then 
resumed their previous immobile  posture. The onset  of 
effects occurred within 5 min  following i.p. injection 
and at the highest dose the effects cont inued  to be 
present for over an hour  and did not  begin to abate unti l  
abou t  75 min  after the injection. Even at 90ra in  the 
mice were quite ataxic and hardly moved. Fol lowing 
chronic adminis t ra t ion  of 10 and  then 32mg/kg  of 
WIN35,197-2,  there was a marked,  almost  tenfold 
decrease in sensitivity to the locomotor  depressant  
effect of  WIN350197-2 (Fig. 2). The differences in 
locomotor  activity were statistically reliable (P < 0.01) 
at doses of 3.2 mg/kg and above. The initial periods of 
immobi l i ty  were shorter and the ataxia less severe in 
mice given W I N  35,197-2 repeatedly. 
Morph ine  induced significant increases in runn ing  
at all the dose used (Fig. 3); maximal  increases occurred 
at 32 and  100mg/kg. Fol lowing chronic 100mg/kg 
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Fig. 2. Locomotor activity changes for 1 h in mice immediately 
following i.p. administration of WIN 35,197-2. Open circles: acute 
administration. Open squares: following chronic administration of 10 
and then 32 mg/kg. Points at C on abscissa: vehicle controls for two 
drug conditions. Data points," average of 5 observations. Brackets." 
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Fig. 4. Locomotor activity for i h in mice immediately follow- 
ing i.p. injection of cocaine. Closed circles: acute administration of 
cocaine: Open circle: following chronic WIN35,197-2 adminis- 
tration. Point at C: vehicle control for cocaine (see Fig. 3 for 
corresponding controls for other groups). Data points." average of 
5observations. Brackets: + 1 SE 
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Fig.& Locomotor activity changes for 1 h in mice immediately 
following i,p. administration of morphine. Closed circles." acute 
administration. Open circles: following chronic administration of 
100mg/kg morphine. Open squares. following chronic adminis- 
tration of 10 and then 32 mg/kg WIN 35,197-2. Data points at C on 
abscissa: vehicle control observations for three drug conditions. Data 
points are average of 5 observations. Brackets." _+ 1 SE 
morphine administration, there was a decrease in 
magnitude of the locomotor-increasing effect of mor- 
phine. This decrease in sensitivity to morphine was not 
caused by an impairment of  running capacity since 
chronic-morphine mice given cocaine ran almost as 
much as naive mice (Fig. 4). Although the cocaine 
response differed reliably between the naive and 
morphine-tolerant animals, that difference was far less 
than the decrement in response to morphine in 
morphine-tolerant animals. 
Mice tolerant to WIN35,197-2 did not exhibit 
tolerance to morphine's locomotor stimulant effects 
(Fig.3). In fact, these animals showed much more 
running to morphine at 100 mg/kg (P < 0.05) than d id  
naive mice. The mice tolerant to WIN 35,197-2 also 
retained sensitivity to cocaine (Fig. 4). 
Naloxone-Induced Jumping. Naloxone (16mg/kg) did 
not induce jumping in the 10-minute period following 
its injection (Fig.5). Mice given various doses of 
morphine 1 h previously, on the other hand, jumped a 
small amount when challenged with this dose of 
naloxone (Fig. 5; left panel). There was a slight sugges- 
tion that maximal morphine priming occurred with the 
32 mg/kg dose. All of the acute doses of WIN 35,197-2 
failed to produce jumping following naloxone adminis- 
tration (Fig. 5; right panel). 
Chronic administration of morphine exaggerated 
the effects of acute morphine administration on 
naloxone-induced jumping. Relatively small amounts 
of jumping occurred in the absence of acute morphine 
in mice receiving morphine chronically. 
Mice treated chronically with WIN 35,197-2 
jumped following naloxone administration (Fig. 5; left 
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Fig. 5. Naloxone-induced jumping for 10min immediately 
following i.p. injection of 16 mg/kg of drug. Naloxone 
injections preceded by vehicle (C on the abscissae), various 
doses of morphine (left panell), or WIN 35,197-2 (right 
panel). Closed circles: acute administration of morphine 
(left panel) or WIN 35,197-2 (right panel) 1 h before 
naloxone. Open circles: following chronic morphine 
administration of 100 mg/kg. Open squares: following 
chronic WIN 35,197-2 administration and acute morphine 
(left panel) or acute WIN 35,197-2 (right panel). Data 
points: average of 5 observations. Brackets: +_ 1 SE 
increase in jumping behavior compared with mice given 
the same doses (3.2 and 10 mg/kg) of WIN 35, 197-2 
acutely (Fig. 5; right panel). This was also borne out in 
the mice tolerant to WIN 35,197-2 given morphine 1 h 
before naloxone challenge. 
Discussion 
WIN 35,197-2, unlike morphine, reduces locomotor 
activity significantly in the mouse. This finding pro- 
vides partial support for the supposition of a different 
mechanism for the two drugs. The reduction in loco- 
motor activity produced by WIN 35,197-2 also differ- 
entiates the compound in the mouse from cyclazocine, 
which induces running that is more resistant to antag- 
onism by naloxone that morphine (e.g., Parker, 1974). 
The effects of WIN 35,197-2 have been antagonized by 
naloxone in the vas deferens of the mouse and the 
guinea-pig ileum (Kosterlitz and Waterfield, 1975) and 
in operant and other behavioral preparations in the 
rhesus monkey (Llewellyn and Woods, unpublished 
observations). 
Tolerance to WIN 35,197-2-induced locomotor ac- 
tivity decreases were observed during chronic adminis- 
tration (Fig. 2). The tolerance did not reduce sensitivity 
to either morphine or cocaine, another indication that 
WIN 35,197-2 may have a pharmacological specificity 
not shared with morphine in the mouse. The mech- 
anisms of the WIN 35,197-2 tolerance and the drugs 
that show cross tolerance with it are interesting topics 
for future work. 
Chronic WIN 35,197-2 administration predisposed 
mice to jumping when naloxone was administered, an 
effect shared morphine. Chronic morphine, under these 
conditions, however, was far more efficacious than 
WIN 35,197-2 as a condition for naloxone-induced 
jumping. Since a common mechanism for this effect is 
inconsistent with the action of WIN 35,197-2 on loco- 
motor activity, we conclude that naloxone-induced 
jumping can probably be activated by more than one 
mechanism. The finding that WIN35,197-2 primes 
mice for naloxone-induced jumping should, on the 
other hand, raise a note of caution for those who would 
infer a morphine-like action from this behavioral effect 
in isolation from others. It is perhaps relevant that the 
characteristics of the withdrawal signs of ketazocine 
and morphine dependence overlap somewhat in the dog 
(Martin et al., 1976). 
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